AI
NEUP

AdvisorShares Investments’s Neuphoria Therapeutics NEUP Stock Holding History

AdvisorShares Investments’s Portfolio NEUP Stock Details NEUP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
252,909
+97,542
+63% +$470K 0.13% 84
2026
Q1 		$632K Buy
155,367
+21,173
+16% +$89.5K 0.12% 102
2025
Q4 		$521K Buy
134,194
+75,631
+129% +$537K 0.09% 110
2025
Q3 		$690K Sell
58,563
-9,170
-14% -$85.1K 0.11% 95
2025
Q2 		$481K Sell
67,733
-1,926
-3% -$11.2K 0.09% 106
2025
Q1 		$397K Buy
+69,659
New +$326K 0.08% 181

Other funds holding NEUP

LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return

AdvisorShares Investments's NEUP Position: Q2 2026 in Review

AdvisorShares Investments increased its Neuphoria Therapeutics (NEUP) stake by 63% in Q2 2026, buying an estimated $470K and bringing the position to 252,909 shares worth $1.11M. The position accounts for 0.13% of the portfolio, ranked #84.

AdvisorShares Investments first reported a position in NEUP in Q1 2025 and has held it in 6 quarters since. 22 funds tracked by Wall St. Rank hold NEUP as of Q2 2026.

  • AdvisorShares Investments held 252,909 shares of Neuphoria Therapeutics worth $1.11M as of Q2 2026.
  • AdvisorShares Investments bought 97,542 Neuphoria Therapeutics shares in Q2 2026, an estimated $470K.
  • Neuphoria Therapeutics made up 0.13% of AdvisorShares Investments's portfolio in Q2 2026, its #84 holding.
  • AdvisorShares Investments first reported a position in Neuphoria Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 22 funds tracked by Wall St. Rank held Neuphoria Therapeutics as of Q2 2026.

Based on AdvisorShares Investments's 13F filing for Q2 2026, filed 11 Aug 2026.